infusion. If the fourfold dosage of Prolastin(R) is given monthly, the patient is unprotected for several daysAdapted from Table 9, page 836. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosisand management of individuals with alpha-1 antitrypsin deficiency....
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Low infusion volumes allow for streamlined treatment PURITY Highly purified through a rigorous process EFFICACY Raises and maintains A1AT levels1 Determining Alpha-1 Diagnosis Examine the clinical nuances of diagnosing Alpha-1 and the journey many patients face. ...
IV infusion rate Aralast NP, Prolastin C, Zemaira: Not to exceed 0.08 mL/kg/min Glassia: Not to exceed 0.04 mL/kg/min Storage Unopened vials Aralast NP, Prolastin C, Zemaira: Temperatures not to exceed 25°C (77°F); avoid freezing (may damage diluent vial) Glassia: 2-8 °C ...
Augmenting the levels of functional protease inhibitor by intravenous infusion is an approach to therapy for patients with A1-PI deficiency. However, the efficacy of augmentation therapy in affecting the progression of emphysema has not been demonstrated in randomized, controlled clinical studies. The ...